{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255130","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.899132+00:00","generated_at":"2026-05-30T01:56:01.933448+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile","bullets":["Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.","Positive phase 3 THRIVE data for veligrotug in active TED; THRIVE-2 topline expected Dec 2024.","Initiated phase 3 REVEAL-1 and REVEAL-2 for VRDN-003; topline data anticipated H1 2026.","VRDN-008 NHP data: 3x half-life vs efgartigimod, 20% deeper IgG reduction; IND planned year-end 2025.","VRDN-006 IND submission by year-end 2024; proof-of-concept IgG reduction data in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255130","json":"https://secwatch.observer/filing/0001193125-24-255130.json","markdown":"https://secwatch.observer/filing/0001193125-24-255130.md","text":"https://secwatch.observer/filing/0001193125-24-255130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/0001193125-24-255130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:56:01.933448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}